Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Cerus Corporation is dedicated solely to safeguarding the worldâs blood supply a...
Cerus Corporation is dedicated solely to safegu...
Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...
Headquartered in New York, BeyondSpring Inc. (B...
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused...
TRACON Pharmaceuticals, Inc. is a clinical stag...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Join the National Investor Network and get the latest information with your interests in mind.